Dual-Target CAR t cells offer new hope for tough lymphoma
NCT ID NCT05098613
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early-phase trial tests a new type of immunotherapy called CD19x22 CAR T cells in people aged 16 and older with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to find a safe dose and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.